Download MendeleyDiscovery of Neutral and Cerebrospinal Fluid Penetrant Transthyretin (TTR) Stabilizers with Heterocyclic Linkers.
Wang, T., Thuma, B.A., Wisniewska, H.M., Lee Johnson, Z., Tu, M., Byrnes, L.J., Cabral, S., Canterbury, D.P., Clemens, J., Coffey, S.B., Dow, R., Dowling, M.S., Fensome, A., Fleming, J., Futatsugi, K., Kalgutkar, A.S., Korczynska, M., Kung, D.W., Lapham, K., Lavergne, S.Y., Limberakis, C., Liu, S., Londregan, A.T., Loria, P.M., Mascitti, V., Moody, A.T., Novak, J.J., Piotrowski, D.W., Sharma, R., Shavnya, A., Stock, I.A., Tess, D.A., Tsai, A.S., Wei, L., Wenzel, Z., Wu, H.(2026) J Med Chem 69: 22942-22953
- PubMed: 42917948 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.6c02318
- Primary Citation Related Structures:
37DK, 37DN, 37EF - PubMed Abstract:
Human transthyretin (TTR) is associated with ATTR amyloidosis. Despite having approved agents against TTR, there is still an unmet medical need to develop novel agents, especially those that could have therapeutic effects in cerebrospinal fluid (CSF). Structure-based drug design (SBDD) in the thyroxine binding pocket of TTR identified a neutral hit. Further optimization led to compound 9, a neutral TTR tetramer stabilizer with single-digit nM SPR Kd potency and with improved ADME profile that could enable it to penetrate to CSF.
- Pfizer Research & Development , 1 Portland Street, Cambridge, Massachusetts02139, United States.
Organizational Affiliation:
